Table 1.
site |
|
expt. b | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abl | 1.2 | −29.4 | 0.5 | −27.7 | 5.6 | 11.3 | −10.8 | −10.8 | |||||||
c-Kit | 7.0 | −28.3 | −4.7 | −26.0 | 4.8 | 12.2 | −9.0 | ||||||||
Lck | 0.4 | −25.3 | 0.0 | −24.9 | 5.2 | 12.4 | −7.3 | −8.7 | |||||||
c-Src(c) | 0.0 | −25.1 | 0.9 | −24.2 | 6.3 | 13.3 | −4.6 | −6.2 | |||||||
c-Src(o) | 4.0 | −23.0 | 0.1 | −18.9 | 4.6 | 7.5 | −6.8 |
Unit in kcal/mol.
The values were derived from the experimentally measured inhibitory potency of Gleevec for unphosphorylated Abl, Lck, and c-Src kinase domain, which is 0.013, 0.43, and 31.1 µM, respectively.14